Skip to main contentAI and Advanced
/
CIPLA · NSEBSE SENSEX77,537.72+0.82%BSE |
NIFTY 5024,231.85+0.64%NSE |
NIFTY BANK57,495.9+0.45%NSE |
NIFTY IT30,673.05+0.79%NSE |
NIFTY AUTO29,301.75+0.40%NSE |
NIFTY FMCG47,863.25+0.82%NSE |
NIFTY PHARMA26,416+0.39%NSE |
NIFTY 50023,512.95+0.54%NSE |
CI
NSE · Equity shares · Biotechnology & Drugs16.00 · 1.13%
Cipla CIPLA
NSE:INR 1,438
BSE:INR 1,475
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for CIPLA
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,422
Day rangeINR 1,427.5 — INR 1,439.4
52-week rangeINR 1,165.7 — INR 1,673
Volume3.28 L
Market cap1.19 L
P/E35.11
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)28,162.59
Net Income (INR Cr)3,879.23
Rev Growth (5 Year %)8.01
EPS Growth (5 Year %)10.01
P/E Ratio35.11
EPS51.46
Research path: Interpret Cipla's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
CIPLACipla1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 42,495.98 | 37,387.04 | 32,717.82 |
| Accumulated Depreciation Total | -6,180.05 | -5,447.75 | -4,853.82 |
| Cash Equivalents | 72.94 | 11.67 | 26.43 |
| Other Liabilities Total | 426.93 | 307.83 | 259.01 |
| Accrued Expenses | 699.55 | 634.83 | 606.91 |
| Long Term Debt | 117.47 | 11.98 | Not available |
| Common Stock Total | 161.56 | 161.52 | 161.47 |
| Other Equity Total | 1,403.97 | 700.17 | 466.04 |
| Other Current Assets Total | 54.52 | 106.06 | 363.58 |
| Prepaid Expenses | 181.05 | 152.81 | 132.91 |
| Total Assets | 42,495.98 | 37,387.04 | 32,717.82 |
| Current Portof LT Debt/Capital Leases | 91.32 | 105.6 | 86.97 |
| Additional Paid-In Capital | 1,707.14 | 1,692.6 | 1,672.84 |
| Cash | 945.28 | 577.02 | 613.64 |
| Total Equity | 34,431.95 | 31,193.45 | 26,706.43 |
| Long Term Investments | 1,621.42 | 922.12 | 1,166.67 |
| Retained Earnings(Accumulated Deficit) | 31,159.28 | 28,639.16 | 24,406.08 |
| Total Common Shares Outstanding | 80.78 | 80.76 | 80.74 |
| Property/Plant/Equipment Total-Gross | 13,806.13 | 11,922.77 | 10,787.11 |
| Tangible Book Valueper Share Common Eq | 341.45 | 324.5 | 272.41 |
| Goodwill Net | 3,754.42 | 3,270.27 | 3,112.04 |
| Total Liabilities | 8,064.03 | 6,193.59 | 6,011.39 |
| Total Debt | 613.77 | 438.19 | 559.41 |
| Short Term Investments | 9,009.9 | 10,020.59 | 7,138.93 |
| Cashand Short Term Investments | 10,028.12 | 10,609.28 | 7,779 |
| Total Receivables Net | 7,099.94 | 6,574.36 | 5,716.17 |
| Notes Payable/Short Term Debt | 140.5 | 80.12 | 247.02 |
| Deferred Income Tax | 153.27 | 53.53 | 185.29 |
| Accounts Receivable-Trade Net | 5,662.11 | 5,543.66 | 4,813.92 |
| Property/Plant/Equipment Total-Net | 7,626.08 | 6,475.02 | 5,933.29 |
| Minority Interest | 88.29 | 95.8 | 95.9 |
| Total Current Liabilities | 7,013.59 | 5,483.96 | 5,245.77 |
| Total Inventory | 6,782.23 | 5,846.01 | 5,449.75 |
| Accounts Payable | 3,229.9 | 2,837.49 | 2,473.98 |
| Other Currentliabilities Total | 2,852.32 | 1,825.92 | 1,830.89 |
| Total Long Term Debt | 381.95 | 252.47 | 225.42 |
| Intangibles Net | 3,096.08 | 1,716.12 | 1,601 |
| Other Long Term Assets Total | 1,295.63 | 952.55 | 700.08 |
| Note Receivable-Long Term | 956.49 | 762.44 | 763.33 |
| Total Current Assets | 24,145.86 | 23,288.52 | 19,441.41 |
| Capital Lease Obligations | 264.48 | 240.49 | 225.42 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio3.06
Price to Sale Ratio4.23
Growth
Debt 5Yr CAGR %-21.16
Margins
Operating Margin 12m13.27
Operating Margin 5y Avg18.01
Net Profit Margin 12m11.88
Net Profit Margin 5y14.85
Yield
Dividend Yield %0.89
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk22.98
Analyst consensus
ConsensusBuy
Consensus score2.32
Analyst opinions37
Strong Sell count1
Sell count3
Hold count11
Buy count14
Strong Buy count8
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
| Lupin | INR 2,395 | 1.10 L | 19.12 | — |
Shareholding
Ownership
- Promoter
- 29.21%
- FII
- 20.20%
- MF
- 20.56%
- Other
- 30.03%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Cipla Shares Gain 2.01% in Today's Session - Moneycontrol.comMarket news · 20 Jul 2026, 3:10 pm
Cipla Shares Gain 2.01% in Today's Session Moneycontrol.com
Pharma index surges 2%; Torrent, Mankind, Cipla, Aurobindo soar up to 5% - Business StandardMarket news · 20 Jul 2026, 2:43 pm
Pharma index surges 2%; Torrent, Mankind, Cipla, Aurobindo soar up to 5% Business Standard
Torrent Pharma, Mankind, Cipla, others lift Nifty Pharma 1.8%; why are pharma stocks rising in weak market? - UpstoxMarket news · 20 Jul 2026, 2:20 pm
Torrent Pharma, Mankind, Cipla, others lift Nifty Pharma 1.8%; why are pharma stocks rising in weak market? Upstox
Cipla shares jump 3% amid pharma rally; Nomura sees Q1 margin recovery, retains Buy - Moneycontrol.comMarket news · 20 Jul 2026, 12:58 pm
Cipla shares jump 3% amid pharma rally; Nomura sees Q1 margin recovery, retains Buy Moneycontrol.com
USFDA issues one observation to Cipla's InvaGen plant after routine cGMP inspection - Indian Pharma PostMarket news · 20 Jul 2026, 7:22 am
USFDA issues one observation to Cipla's InvaGen plant after routine cGMP inspection Indian Pharma Post
Cipla's New York-facility gets 1 observation from FDA - ETPharma.comMarket news · 20 Jul 2026, 7:21 am
Cipla's New York-facility gets 1 observation from FDA ETPharma.com
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.13.0000 per share(650%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
ShareKeyX Community
Discussion and sentiment for Cipla
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- CIPLA
- BSE Code
- 500087
Questions
Stock FAQ
What is the symbol and ISIN of Cipla?
Cipla has the symbol CIPLA and ISIN - INE059A01026.
What is the current price of Cipla?
Cipla is currently trading at INR 1,438.00.
What are the year high and year low of Cipla?
Cipla has a year high of INR 1,673.00 and a year low of INR 1,165.70.
What is the market capitalization of Cipla?
Cipla has a market capitalization of INR 1.19 lakh crore.
What is the P/E ratio of Cipla?
Cipla has a P/E ratio of 35.11.
What is the dividend yield of Cipla?
Cipla has a dividend yield of 0.89%.
How is the financial performance of Cipla based on revenue, net income, and EPS?
Cipla has revenue of INR 28,162.59 crore, net income of INR 3,879.23 crore, and EPS of INR 44.69.
What is the book value of Cipla?
Cipla has a book value of NA.
What is the debt-to-equity ratio of Cipla?
Cipla has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Cipla?
Cipla has a price-to-book ratio of NA and a price-to-sales ratio of 4.23.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.